FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | |
|----------------------|-----------|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | |
| Estimated average bu | urden | | | | | | |
| hours per response: | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | () . | | | | Company Ac | | | | | | | | |
|---|---|---|---------------------------------------|--|--|--------|--|------------------------|---|------------------------|---|-------------------------|--|---|--|-------|--|--|
| LILLY ENDOWMENT INC (Last) (First) (Middle) 3.1 | | | | | 2. Issuer Name and Ticker or Trading Symbol ELI LILLY & Co [LLY] 3. Date of Earliest Transaction (Month/Day/Year) 06/16/2023 | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner | | | | | |
| | | | | | | | | | | | | | | | er (give title | X | Other (below) | |
| | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| | | | | | | | | | | | | | | Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
| (City) | 'ip) | Ru | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | | |
| | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | | Table | l - Non-Deriva | tive S | Secu | rities | Acc | quire | ed, D | isposed (| of, or | Benefic | cially | O wr | ned | | | |
| 1. Title of | Security (Ins | 2. Transaction Date (Month/Day/Ye | ar) Ex | 2A. Deemed Execution Date, if any (Month/Day/Year) | | Co | ansac | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a | | | and 5) Secu | | icially d | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | Co | ode | v | Amount | (A) or (D) | Price | | Repor Transa (Instr. | | | | | |
| Commor | Stock | 06/16/2023 | 3 | | | | S | | 5,700 | D | \$454.3 | 39 ⁽¹⁾ | 101, | 440,757 | | D | | |
| Common | Stock | 06/16/2023 | 3 | | | | S | | 17,231 | D | \$455.761 ⁽² | | 2) 101,423,526 | | | D | | |
| Commor | Stock | | 06/16/2023 | 3 | | | | S | | 2,084 | D | \$456.4 | .498 ⁽³⁾ 1 | | 101,421,442 | | D | |
| | | Tab | le II - Derivati (e.g., pu | | | | | | | posed of , converti | | | | Owne | ed | | | |
| 1. Title of Derivative Security (Instr. 3) | Derivative Conversion Date Execuses (Month/Day/Year) if any | | | 4. Transaction Code (Instr. 8) Solution Securit (A) or Dispos of (D) (Instr. 3 and 5) Code V (A) (| | | rative rities ired r osed) | (Month/Day/Year) ees d | | | Amo Secu Und Deri Secu (Inst | Amount of Securities | | Price of erivative deciriative security str. 5) Securities Beneficia Owned Following Reported Transacti (Instr. 4) | | , (| 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$454.00 to \$454.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$455.24 to \$456.23, inclusive.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$456.31 to \$456.60, inclusive.

Remarks:

/s/Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment

06/20/2023

Inc.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.